Catalent Applied Drug Delivery institute Welcomes Accomplished Life Sciences Leader Dr. Ralph Lipp to Advisory Board and Terry Robinson as Executive Director

Somerset, NJ – March 7, 2013

The Catalent Applied Drug Delivery Institute announced today that Dr. Ralph Lipp a well-known pharmaceutical industry executive and inventor, will become the founding member of the Institute’s Advisory Board.  Dr. Lipp brings over 20 years of industry and academic experience to the Institute, having previously served as Vice President, Pharmaceutical Sciences R&D at Eli Lilly and Company, and in R&D leadership roles at Schering AG. He has brought dozens of new medical entities into clinical studies, and contributed to launch of 10 new treatments. Dr. Lipp’s accomplishments include more than 20 patents, including 5 marketed medicines, and more than 100 additional scientific publications. His broad research experience includes oncology, cardiovascular disease, central nervous system disorders, women’s health, in vivo diagnostics, and dermatology.

“I look forward to leveraging my experience and knowledge to help the Institute accomplish its important mission of delivering better treatments to patients,” Dr. Lipp commented.  “I believe enhanced adaption of applied drug delivery technologies and increased collaboration across the industry and with academia will help innovator companies develop better products, resulting in improved outcomes for patients.” Dr. Lipp is currently President and CEO of Lipp Life Sciences, LLC.

The Institute also has appointed Ms. Terry Robinson as Executive Director. Since joining Catalent Pharma Solutions five years ago, Ms. Robinson has fostered countless collaborations with top pharmaceutical innovators, bringing business and scientific leaders together to help develop better treatments. Mrs. Robinson brings over 25 years of health care experience at Eli Lilly and Company and Amgen, Inc. to her new role leading the Institute. Ms. Robinson will work closely with the Institute’s Advisory Board to advance the use of drug delivery technologies to bring more and better treatments to patients via new technology development, increased cross-industry and academic collaborations, advanced industry education, research and publications.

“The welcome additions of Dr. Lipp and Ms. Robinson are a significant step in building a strong foundation for the Institute,” noted Dr. Kurt Nielsen, a Director of the Institute and Catalent’s SVP of R&D. “Terry’s ability to build collaborative partnerships, combined with the well-known drug development and delivery expertise of Dr. Lipp and other future Advisory Board members, will enable the Institute advance the future of drug delivery to improve patient treatments”.

Meet The Institute at DCAT

Join the Catalent Applied Drug Delivery Institute at DCAT Week 2013, the annual meeting of the Drug, Chemical & Associated Technologies Association, Inc., where Dr. Kurt Nielsen will team up with Dr. Ralph Lipp, and Dr. Nigel Langley of BASF Corporation to lead a panel discussion on “Excipients: Innovation in Bioavailability Enhancement.” The discussion, which will take place Tuesday, March 12, 2013, from 9:00AM – 11:30 AM, at the InterContinental Hotel in New York City, and will feature insights on industry needs, the complex regulatory environment, the future of bioavailability, and concept enhancements and improvements to help drug developers overcome challenges in bringing new, innovative drugs to market. The expert panel is also to include Dr. David Lyon, Senior Vice President, Research, at Bend Research; Dr. Keith Horspool, Vice President, Pharmaceutics, at Boehringer Ingelheim; and Dr. Mansur Kahn, Director of the Division of Product Quality Research at the U.S. Food and Drug Administration (FDA). For event information or to register for DCAT Week 2013, visit:

To request an interview with Dr. Kurt Nielsen, Dr. Ralph Lipp, or Mrs. Terry Robinson,Contact: Holly Rackett

About the Catalent Applied Drug Delivery Institute:

The mission of the Catalent Applied Drug Delivery Institute is to promote collaboration between industry and academia, provide applied drug delivery education and training, and accelerate adoption of innovative drug delivery technologies to help develop better treatments, as well as encourage industry engagement on major issues pertaining to drug development, formulation and delivery.  The Institute welcomes additional collaborations and technology partnerships.

Contact Holly Rackett for more information on upcoming Institute programs and initiatives, including:

  • 2nd Annual Academic Competition for Life Science Leaders of Tomorrow
  • Annual Drug Delivery Technology Landscape Survey
  • Upcoming Drug Development and Delivery Education/Training Sessions: “Bioavailability Enhancement Using Lipid-based Drug Delivery and Modified Release Technologies”
About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across five continents, and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably suplied. ™

About Lipp Life Sciences LLC

Dr. Lipp is the President and CEO of Lipp Life Sciences LLC, focused on the creation of innovative, patient-centered product opportunities to address unmet medical need, and advising clients in the areas of R&D, related business models and processes.